Inhalation Sciences AB has received a Purchase Order, worth EUR 125.8 million from an international distributor for Asia. The new order is for PreciseInhale, ISAB's unique aerosol generation system, with additional modules. PreciseInhale is unique within inhaled drug development as a 'precision dosing' system.

Unlike standard 'tower testing' systems, it customizes the individual aerosol dose to individual test animals, achieving exceptionally high-precision and predictive data in the preclinical stages of inhaled drug development. ISAB has recently increased the focus of its commercial activities around its Inhalation Research Services (IRS) capabilities. Nevertheless, the company's unique platform still attracts direct purchase interest, often from academic research organizations looking to be able to offer testing and data.